GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Operating Margin %

Ocular Therapeutix (Ocular Therapeutix) Operating Margin %

: -135.46% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Ocular Therapeutix's Operating Income for the three months ended in Dec. 2023 was $-20.05 Mil. Ocular Therapeutix's Revenue for the three months ended in Dec. 2023 was $14.80 Mil. Therefore, Ocular Therapeutix's Operating Margin % for the quarter that ended in Dec. 2023 was -135.46%.

Good Sign:

Ocular Therapeutix Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Ocular Therapeutix's Operating Margin % or its related term are showing as below:

OCUL' s Operating Margin % Range Over the Past 10 Years
Min: -3509.59   Med: -2106.28   Max: -140.96
Current: -140.97


OCUL's Operating Margin % is ranked better than
52.59% of 1025 companies
in the Biotechnology industry
Industry Median: -179.29 vs OCUL: -140.97

Ocular Therapeutix's 5-Year Average Operating Margin % Growth Rate was 49.20% per year.

Ocular Therapeutix's Operating Income for the three months ended in Dec. 2023 was $-20.05 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-82.38 Mil.


Ocular Therapeutix Operating Margin % Historical Data

The historical data trend for Ocular Therapeutix's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,029.86 -361.13 -179.30 -152.74 -140.96

Ocular Therapeutix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -137.56 -168.60 -135.45 -127.41 -135.46

Competitive Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Operating Margin % falls into.



Ocular Therapeutix Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ocular Therapeutix's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-82.382 / 58.443
=-140.96 %

Ocular Therapeutix's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-20.05 / 14.801
=-135.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix  (NAS:OCUL) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ocular Therapeutix Operating Margin % Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (Ocular Therapeutix) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730